Chronic Myeloid Leukemia
Conditions
Interventions
1:NK infusion
Sponsors
Hematopathy Hospital of Xi'an International Medical Center Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 60 Years
Inclusion criteria
Inclusion criteria: 1. Patients with Ph + chronic myelocytic leukemia (Ph + CML) with age >= 18 years old (the general condition is good and can be relaxed appropriately); 2. Patients in the chronic phase of CML without history of accelerated or cataclysmic phase; 3. The patients treated with approved TKI were treated for more than 3 months and the daily time was fixed; 4. Patients who did not achieve the main molecular biological response MMR (BCR / ablis >= 1%) or complete hematological response (CHr) were treated regularly by TKI; 5. The patient's economic situation does not allow to continue TKI treatment; 6. The patient or client agrees to participate in the trial and has signed the informed consent.
Exclusion criteria
Exclusion criteria: 1. Patients who have previously received hematopoietic stem cell transplantation or other immune cell therapy; 2. Patients with malignant tumor other than CML have dysfunction of important organs of heart, brain, liver and kidney; 3. Patients with severe infection or receiving anti tuberculosis treatment; 4. Patients who can not guarantee to complete the necessary treatment plan and follow-up observation; 5. Pregnant and lactating women; 6. Patients who are considered unsuitable for clinical observation by other researchers; 7. Patients who participated in other clinical trials within 4 weeks before the start of this study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| BCR-ABL1<0.01; | — |
Secondary
| Measure | Time frame |
|---|---|
| WBC:4~10×109/L;PLT:450×109/L;CD3-CD56+CD16+NK; | — |
Countries
China
Contacts
Public ContactYao Hanbing
Xi'an International Medical Dream Life Science Research Institute
Outcome results
None listed